Skip to Content
  • Annual report 2022
    • Management review 2022
    • Small country, big agency
    • Fimea active in EU-level development work
    • A year of many legislative changes for Fimea and operators
    • Fimea has a strong role in pharmaceutical reform
    • Fimea continued to promote medication safety and safe pharmacotherapy
    • Drug advice provided in remote pharmacy services should be improved
    • A Finnish study: Safeguarding efficient antibacterial therapy calls for quick measures
    • Fimea develops services starting from the medical device operator and device register
    • Fimea’s customer satisfaction improved
    • Regulation of veterinary medicines also safeguards human health
    • Personnel training emphasises the sense of community
    • Fimea’s premises in Kuopio moved to Lake Kallavesi
  • Annual report 2021
    • Fimea’s Year 2021
      • COVID-19 continued to generate work
      • Enabling joint discussion and good interaction are important lessons learned for the period 2022-2023
    • Economy
      • Structure of Fimea's funding 2021
    • Statistics
      • Shortage notifications 2016–2021
      • Inspections by control area 2017–2021
      • Marketing authorisation services in 2021
      • Number of marketing authorisations (marketing authorisations valid) 2017–2021
    • Pharmaceutical information
      • Examination of the medicines data repository continued
      • Getting to know the Safe Pharmacotherapy Guide that promotes medication safety
    • Responsibility
      • Responsibility at Fimea – Responsibility report 2021
        • Sustainable well-being through safe and effective medicines and medicinal products
        • Sustainable well-being and economy through rational use of medicines
        • Functional distribution of medicines
        • Impactful supervision
    • Fimea in brief
      • Fimea’s strategy journey continued with the restructuring of its organisation
      • Meds75+ promotes medication safety in older people - the goal is international recognition
  • Annual report 2020
    • Fimea's Year 2020
      • Travel restrictions speeded up the adoption of remote inspections
      • Fimea is strongly involved in the management of the corona epidemic
    • Economy
      • Structure of Fimea's funding
    • Statistics
      • Number of marketing authorisations (marketing authorisations valid) 2016–2020
      • Inspections by control area 2016-2020
      • Shortage notifications 2015–2020
      • Marketing authorisation services in 2020
    • Pharmaceutical information
      • The use of the Meds75+ database in healthcare improves the medication safety of the elderly
    • Responsibility
      • Accessible to all
    • Fimea in brief
      • Sustainable wellbeing through safe medicines and medicinal products, combined with effective service
  • Fimea Sustainability Report 2022
    • Director General’s review and Fimea’s sustainability policies
    • Meeting the demand for medicines and medical products
    • Safe medicinal treatment of production animals, environmental protection and reduction of national drug wastage
    • Case example: Development of an antimicrobial consumption application
    • Supporting innovation and developing infrastructure
    • Safety of medicines and the production of reliable medicines information
    • Case example: Nitrosamine impurities in medicines challenge the authorities and industry
    • Fimea’s footprint – social, ecological and economic sustainability

 

  • Annual report 2022
    • Management review 2022
    • Small country, big agency
    • Fimea active in EU-level development work
    • A year of many legislative changes for Fimea and operators
    • Fimea has a strong role in pharmaceutical reform
    • Fimea continued to promote medication safety and safe pharmacotherapy
    • Drug advice provided in remote pharmacy services should be improved
    • A Finnish study: Safeguarding efficient antibacterial therapy calls for quick measures
    • Fimea develops services starting from the medical device operator and device register
    • Fimea’s customer satisfaction improved
    • Regulation of veterinary medicines also safeguards human health
    • Personnel training emphasises the sense of community
    • Fimea’s premises in Kuopio moved to Lake Kallavesi
  • Annual report 2021
  • Annual report 2020
  • Fimea Sustainability Report 2022
  • Valitse kieli Suomi
  • Välj språket Svenska
  • Select language English

  • Management review 2022

  • Small country, big agency

  • Fimea continued to promote medication safety and safe pharmacotherapy

  • A year of many legislative changes for Fimea and operators

  • Fimea’s customer satisfaction improved

P.O. Box 55, 00034 FIMEA FI

029 522 3341

[email protected]

© Fimea 2023

Fimea promotes the health and safety of the population by regulating medicinal, medical devices, blood and tissue products, biobanks and by developing the pharmaceuticals sector.

Information about this website

  • Data protection (in Finnish)
  • Cookie policies
  • Accessibility statement